Literature DB >> 10452988

Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation.

R Bianchi1, U Grohmann, Carmine Vacca, M L Belladonna, M C Fioretti, P Puccetti.   

Abstract

Ligation of CD40 on dendritic cells (DC) triggers production of IL-12. Using an adoptive transfer model we have previously shown that rIL-12 acts directly on DC to enhance presentation of an otherwise poorly immunogenic tumor peptide. Using the same experimental model, we now describe a similar adjuvanticity of CD40 ligation on peptide presentation by DC. We also explore the possibility that the IL-12 resulting from CD40 ligation directly affects the APC function of DC, mediating or contributing to the adjuvant effect of CD40 ligation. CD40 engagement in vitro and rIL-12 at concentrations in the range induced by CD40 ligation were equally effective in priming DC for presentation of the tumor peptide in vivo. Remarkably, the copresence in vitro of neutralizing Ab to IL-12, but not to TNF-alpha, IL-1beta, or IFN-gamma, ablated the enhancing effect of CD40 engagement on the APC function of DC. These data suggest a major role for autocrine IL-12 in DC modulation via CD40 ligation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452988

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

2.  Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.

Authors:  H N Lode; R Xiang; U Pertl; E Förster; S P Schoenberger; S D Gillies; R A Reisfeld
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

3.  Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity.

Authors:  Bartosz Wiernicki; Sophia Maschalidi; Jonathan Pinney; Sandy Adjemian; Tom Vanden Berghe; Kodi S Ravichandran; Peter Vandenabeele
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

4.  Rapamycin modulates the maturation of rat bone marrow-derived dendritic cells.

Authors:  Yingjun Ding; Xiang Cheng; Tingting Tang; Rui Yao; Yong Chen; Jiangjiao Xie; Xian Yu; Yuhua Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

5.  Fibroblast and T cells conditioned media induce maturation dendritic cell and promote T helper immune response.

Authors:  Masoumeh Asadi; Farah Farokhi; Nowruz Delirezh; Meysam Ganji Bakhsh; Vahid Nejati; Keykavos Golami
Journal:  Vet Res Forum       Date:  2012       Impact factor: 1.054

6.  IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations.

Authors:  María Paula Morelli; María Paula Del Medico Zajac; Joaquín Miguel Pellegrini; Nicolás Oscar Amiano; Nancy Liliana Tateosian; Gabriela Calamante; María Magdalena Gherardi; Verónica Edith García
Journal:  Front Cell Infect Microbiol       Date:  2020-09-23       Impact factor: 5.293

Review 7.  NHS-IL12, a Tumor-Targeting Immunocytokine.

Authors:  John W Greiner; Y Maurice Morillon; Jeffrey Schlom
Journal:  Immunotargets Ther       Date:  2021-05-27

8.  Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.

Authors:  Peter Terness; Thomas M Bauer; Lars Röse; Christoph Dufter; Andrea Watzlik; Helmut Simon; Gerhard Opelz
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

Review 9.  Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy.

Authors:  Julia Terhune; Erik Berk; Brian J Czerniecki
Journal:  Vaccines (Basel)       Date:  2013-11-21

10.  Oxazolone-induced contact hypersensitivity reduces lymphatic drainage but enhances the induction of adaptive immunity.

Authors:  David Aebischer; Ann-Helen Willrodt; Cornelia Halin
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.